Drugs / BC02
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04239313 Comparator | May 2020 → Feb 2021 | tuberculosis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05284812 Comparator | Feb 2022 → Jun 2024 | tuberculosis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04239313 ↗ |
| Known as | BCG CpG DNA compound adjuvants system 02 | “BC02 (BCG CpG DNA compound adjuvants system 02) is a novel compound adjuvant with independent intellectual properties” PMID 36560565 ↗ Dec 2022 |
| Modality | Other / unclassified | “BC02 (BCG CpG DNA compound adjuvants system 02) is a novel compound adjuvant” PMID 36560565 ↗ Dec 2022 |
| Route | Intramuscular | “injection into the deltoid muscle of the upper arm” NCT05284812 ↗ |